Stoffel B, Krämer K, Mayer H, Beuth J
Institute of Medical Microbiology and Hygiene, University of Köln, Germany.
Anticancer Res. 1997 May-Jun;17(3C):1893-6.
The immunomodulating abilities of commercially available mistletoe extract standardized for the galactoside-specific lectin (mistletoe lectin-1, ML-1) and sodium selenite (Se) were evaluated in BALB/c-mice and compared to non-treated control animals. Following the optimal schedule of administration (ML-1: 1ng/kg BW; days 1, 2, 3, 5 and Se: 3,5 micrograms/kg BW for 7 subsequent days before evaluation) yielded enhanced counts (thymocytes; peritoneal macrophages, MO; peripheral blood leukocytes; lymphocytes, PBL; monocytes, PBM) and activities (CD-25 positive PBL, MAC-3 positive PBM) of desired immune cells reaching statistical significance for most parameters. However, combined administration of ML-1 and Se proved to be superior to monotherapy since immune cell counts (thymocytes, leukocytes, PBL, PBM) and activities (CD-25 positive PBL) exceeded values obtained after monotherapy. These data are in favour of therapeutical strategies in complementary oncology and suggest that the combination of defined immunomodulating substances might positively enhance the efficacy.
评估了市售的、针对半乳糖苷特异性凝集素（槲寄生凝集素-1，ML-1）和亚硒酸钠（Se）标准化的槲寄生提取物的免疫调节能力，并在BALB/c小鼠中进行了比较，同时与未处理的对照动物进行对比。按照最佳给药方案（ML-1：1ng/kg体重；第1、2、3、5天，以及Se：3.5微克/千克体重，在评估前连续7天给药）给药后，所期望的免疫细胞数量（胸腺细胞、腹腔巨噬细胞、外周血白细胞、淋巴细胞、单核细胞）和活性（CD-25阳性淋巴细胞、MAC-3阳性单核细胞）增加，大多数参数达到统计学显著水平。然而，ML-1和Se联合给药被证明优于单一疗法，因为免疫细胞数量（胸腺细胞、白细胞、淋巴细胞、单核细胞）和活性（CD-25阳性淋巴细胞）超过了单一疗法后的数值。这些数据支持了辅助肿瘤学中的治疗策略，并表明特定免疫调节物质的组合可能会积极提高疗效。
